Fang Ye

Fang Ye


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2021 in Medical Science Monitor
Verified
Journal Article
Open access
JZJingwen Zhou
Jingwen Zhou
XZXiaolong Zhang
Xiaolong Zhang
LWLingfeng Wan
Lingfeng Wan
JYJun Yu
Jun Yu
TLTianci Li
Tianci Li
FYFang Ye
Fang Ye
Zi Qi Decoction Alleviates Liver Fibrosis by Inhibiting the Toll-Like Receptor 4 (TLR4)-Related Nuclear Factor kappa b (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) Signaling Pathways - Article abstract #929438

26 March 2021 in Medicine
Verified
Journal Article
Open access
JZJingwen Zhou
Jingwen Zhou
YCYidi Chen
Yidi Chen
JYJun Yu
Jun Yu
TLTianci Li
Tianci Li
ZLZiyu Lu
Ziyu Lu
FYFang Ye
Fang Ye
Background: Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease characterized by excess accumulation of fat in hepatocytes. Because no drug has been approved for NAFLD treatment, this work analyzed the effects of agents resulting from 2 research hotspots, metabolic target agents, and natural plant drugs, on NAFLD with network meta-analysis. Methods: Public databases were searched through August 14, 2020. Randomized controlled trials that compared obeticholic acid, elafibranor, cenicriviroc, selonsertib, curcumin, silymarin, and resveratrol to placebo were included. Liver pathology improvement, hepatic biochemical indicators, and lipid metabolism indicators were analyzed. Results: Thirty-five studies were included in the meta-analysis. Obeticholic acid was found to significantly increase the frequency of liver biopsy improvement compared to placebo (OR: 2.10; 95% CI: 1.60, 2.77). The ranking results among the hepatic biochemical indicators showed that obeticholic acid (94.9%) and elafibranor (86.3%) have a relative advantage in reducing alanine aminotransferase (ALT) levels, and obeticholic acid also had an advantage (95.4%) in reducing aspartate aminotransferase (AST) levels. Considering lipid metabolic indicators, elafibranor (expSMD: 0.01; 95% CI: 0.00, 0.05; SUCRA: 100%), and obeticholic acid (expSMD: 0.48; 95% CI: 0.28,0.84; SUCRA: 75.6%) significantly reduced triglyceride (TG) levels compared with placebo; moreover, obeticholic acid, but not elafibranor, caused a serious increase in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels and a decrease in high-density lipoprotein cholesterol (HDL-C) levels. Conclusions: Novel metabolic targeted agents generally have better effects than natural plant drugs, especially obeticholic acid, and elafibranor. However, obeticholic acid showed serious adverse effects such as increasing LDL-C levels and decreasing HDL-C levels. Curcumin showed potential advantages for NAFLD but lacked statistical significance.

19 June 2026 in Medicine
Verified
Journal Article
Open access
JYJun Yu
Jun Yu
JZJingwen Zhou
Jingwen Zhou
MSMeng Sun
Meng Sun
JWJie Wan
Jie Wan
XCXiaoying Chen
Xiaoying Chen
FYFang Ye
Fang Ye
Identifying prognostic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD) remains critical. This study investigates the association of the pan-immune inflammation value (PIV) and systemic immune inflammation index (SII) with mortality in the MASLD population. This cohort study used data from the National Health and Nutrition Examination Survey 1999 to 2018, associated with the National Death Index records, including 6252 patients with MASLD. Natural logarithms of PIV and SII (lnPIV, lnSII) were analyzed due to right-skewed distributions. Kaplan–Meier survival curves and multivariate Cox proportional hazards models were employed to assess the relationships between lnPIV, lnSII, all-cause and cardiovascular disease (CVD) mortality. Restricted cubic splines were applied to explore nonlinear trends, and segmented Cox regression was used to analyze threshold effects. Model performance was evaluated using the concordance index, time-dependent receiver operating characteristic curves, and calibration plots. Subgroup analyses were conducted to assess the robustness of the findings across different populations. Over a median follow-up of 9.17 years, 1154 all-cause deaths and 373 CVD-related deaths were recorded. Compared with individuals in the lowest quartile (Q1), those in the highest quartile (Q4) of lnPIV and lnSII had multivariable-adjusted hazard ratios of 1.36 (95% confidence interval [CI], 1.08–1.70) and 1.28 (95% CI, 1.02–1.61) for all-cause mortality, and 1.59 (95% CI, 1.00–2.52) and 1.76 (95% CI, 1.18–2.62) for CVD mortality, respectively. Nonlinear associations were observed between lnPIV, lnSII, and all-cause mortality, with thresholds identified at lnPIV = 6.015 and lnSII = 6.342. No significant associations were detected ( P > .05) below these thresholds, whereas a significant positive association was found above the thresholds ( P < .001). In contrast, a linear relationship was observed between lnPIV, lnSII, and CVD mortality. Time-dependent receiver operating characteristic curves and calibration plots demonstrated good model discrimination and calibration. No significant interactions were found across most subgroups ( P for interaction > .05). Elevated PIV and SII are associated with an increased risk of all-cause and CVD mortality in MASLD. A significantly higher hazard of all-cause mortality was observed when lnPIV and lnSII were above specific thresholds. They are potential tools that require external validation in patients with MASLD.

1 August 2022
Verified
Journal Article
Closed access
LLLexin Wei Lexin
Lexin Wei Lexin
WWWeiyi Li Weiyi
Weiyi Li Weiyi
TTTing Tian Ting
Ting Tian Ting
NNNing Zhang Ning
Ning Zhang Ning
SSShijing Yang Shijing
Shijing Yang Shijing
FYFang Ye
Fang Ye